Health News Releases

  • Today July 12
Louis Denis, MD, Chief Medical Officer, Byondis
June 04, 15:15
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation
June 04, 11:40
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com%2F&esheet=54264219&newsitemid=20250603992751&lan=en-US&anchor=Takeda&index=1&md5=06ff112e45cab46a48bacf2cabee3e8
June 04, 10:40
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54263182&newsitemid=20250602546858&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 03, 10:00
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54262852&newsitemid=20250531886517&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 02, 11:25
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.protagonist-inc.com%2F&esheet=54262872&newsitemid=20250531031305&lan=
HistoSonics Non-Invasive Edison Histotripsy System
June 01, 10:30
HistoSonics’ Edison Histotripsy System Gains Great Britain Early Market Access Under Unmet Clinical Needs Authorisation
HistoSonics (https://histosonics.com/), announced today that its Edison Histotripsy System for the non-invasive destruction of liver tumours has been granted controlled early limited market access in
May 30, 10:40
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/
Exterior view of the New Building, Yamanashi Plant
May 29, 15:35
Rigaku Completes New Building at Yamanashi Plant
Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; herei
BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.
May 29, 15:30
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation
May 29, 09:14
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib, a potentially be
Nurse Naomi Oyoe Ohene Oti from Ghana – Winner of Aster Guardians Global Nursing Award 2025 (Photo:
May 28, 16:50
Ghana’s Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000
Nurse Naomi Ohene Oti from Ghana has been named the winner of the Aster Guardians Global Nursing Award 2025, selected from 100,000 applications from 199 countries. An Oncology Nurse Specialist and Hea
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific adv
May 28, 16:00
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug deve
key visual image
May 28, 16:00
Revolutionizing Healthcare: Ubitus and MacKay Memorial Hospital Present AI Robot Collaboration at GTC Taiwan
Ubitus, a global leader in cloud streaming and AI solutions, announced its collaboration with MacKay Memorial Hospital to unveil AI-powered multi-modal medical robots at NVIDIA GTC Taiwan 2025. The pr
May 28, 14:32
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF
May 28, 09:05
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR · Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of
May 28, 08:44
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54259352&newsitemid=20250527716937&lan=en-US&anchor=TSE%3A4
May 27, 17:06
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
The Royal Marsden NHS Foundation Trust (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.royalmarsden.nhs.uk%2F&esheet=54258962&newsitemid=20250527348807&lan=en-US&anchor=The+Roya
May 25, 14:25
BeiGene Presents Pioneering Cancer Research at ASCO 2025 - Redefining Treatment Across Hematology and Solid Tumors
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54258273&newsitemid=20250522213317&lan=en-US&anchor=BeiGene&index=1&md5=b2e553cdb745c6a1895871c2f51
May 23, 13:55
Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
May 23, 11:30
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual M
May 23, 11:30
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
May 23, 10:45
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific adv
May 22, 15:25
Novotech Honored with Triple Win in 2025 Pharmaceutical Technology Excellence Awards
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies, is proud to announce its
May 22, 08:40
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demons
May 18, 15:15
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) te
25 per page50 per page75 per page100 per page